The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes

Hematopoietic stem cell graft cellular composition has been generally accepted to impact outcomes. Recent studies question this hypothesis. We conducted a single‐center retrospective study of sixty‐one pediatric BMT recipients for malignant (68%) and nonmalignant diseases (32%) examining effects of graft composition on engraftment, acute GVHD, chronic GVHD, and survival at day 100 and 1 year. Grafts contained a median of 3.63 x 08 TNC/kg (range: 0.031‐10.31 x 108 TNC/kg) and 4.09 x 106 CD34+/kg (range: 0.76‐24.15 x 106 CD34+/kg) with median neutrophil and platelet engraftment times of 17 and 29 days, respectively. A univariate analysis showed a trend for increasing TNC and increasing time to neutrophil engraftment HR: 0.875; CI: 0.075‐1.001). Increasing CD34+ counts shortened time to platelet engraftment (HR: 1.085; CI: 1.015‐1.161). No significant relationship was found between TNC, CD34+, or CD3+ and acute or chronic GVHD. TNC or CD34+ did not affect day 100, 1‐year survival, or 2‐year survival. Increasing CD3+ counts demonstrated a negative trend on day 100 survival (HR: 1.108; CI: 1.001‐1.036) but not 1‐year survival or 2‐year survival. These results add additional data questioning the effect of graft composition on outcomes in pediatric BMT patients with important ramifications for the management of donors.

[1]  H. Greinix,et al.  Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  M. Remberger,et al.  Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[4]  M. Perales,et al.  Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  U. Pötschger,et al.  No impact of total or myeloid Cd34+ cell numbers on neutrophil engraftment and transplantation-related mortality after allogeneic pediatric bone marrow transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  T. Lamparelli,et al.  Quality of harvest and role of cell dose in unrelated bone marrow transplantation: An Italian Bone Marrow Donor Registry–Gruppo Italiano Trapianto di Midollo Osseo Study , 2014, Hematology.

[7]  E. Garrett-Mayer,et al.  Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT , 2013, Bone Marrow Transplantation.

[8]  G. Switzer,et al.  Immediate and long-term somatic effects, and health-related quality of life of BM donation during early childhood. A single-center report in 210 pediatric donors , 2013, Bone Marrow Transplantation.

[9]  D. Stroncek,et al.  Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. , 2010, Blood.

[10]  H. Greinix,et al.  Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations , 2010, Bone Marrow Transplantation.

[11]  J. Wagner,et al.  The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Labopin,et al.  Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. El-Sharkawy,et al.  Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation , 2005, Bone Marrow Transplantation.

[14]  M. Labopin,et al.  Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. , 2003, Blood.

[15]  S. Heimfeld.  HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? , 2003, Bone Marrow Transplantation.

[16]  S. Chevret,et al.  Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. , 2002, Blood.

[17]  S. Chevret,et al.  Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia , 2001, Bone Marrow Transplantation.

[18]  A. Nademanee,et al.  Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program , 2000 .

[19]  J. Goldman.  A special report: bone marrow transplants using volunteer donors--recommendations and requirements for a standardized practice throughout the world--1994 update. The WMDA Executive Committee. , 1994, Blood.